p-Glycoprotein expression as a predictor of breast cancer recurrence

Annals of Surgical Oncology

Volumn 3, Issue 1, 1996, Pages 8-14

  Gregorcyk, Sharon ^a   Kang, Yuan ^a   Brandt, Dörthe ^a   Kolm, Paul ^b   Singer, Gerry ^c   Perry, Roger R ^a,c  

^a Division of Surgical Oncology   (United States)

^b Office of Biostatistics   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; Multidrug resistance; P glycoprotein Prognostic factor; Recurrence

Indexed keywords

GLYCOPROTEIN P;

AGED; ARTICLE; BREAST TUMOR; CANCER STAGING; COMPARATIVE STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RETROSPECTIVE STUDY;

AGED; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; P-GLYCOPROTEIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 0029688176     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02409045     Document Type: Article

References (35)

1. The American Cancer Society. Cancer facts and figures, 1995. Atlanta, GA: The American Cancer Society.
2. Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989;320:473-8.
3. Piccart MJ, deValeriola D, Parideans R, et al. Six-year results of a multimodality treatment strategy for locally advanced breast cancer. Cancer 1988;62:2501-6.
4. Winchester DP. Adjuvant therapy for node-negative breast cancer: the use of prognostic factors in selecting patients. Cancer 1991;67(suppl): 1741-3.
5. Clark GM, McGuire WL. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 1988; 15(suppl):20-5.
6. Osborne CK. Prognostic factors for breast cancer: have they met their promise? J Clin Oncol 1992;10:679-82.
7. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 1976;455:152-62.
8. Beck WT. The cell biology of multiple drug resistance. Biochem Pharmacol 1987;36:2879-87.
9. Wallner J, Depisch D, Gsur A, Gotzl M, Haider K, Pirker R. MDR1 gene expression and its clinical relevance in primary gastric carcinomas. Cancer 1993;71:667-71.
10. Mickisch G, Bier H, Bergler W, Bak M, Tsschada R, Alken P. P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary human renal cell carcinomas. Urol Int 1990;45:170-6.
11. Chan HSL, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991;325:1608-14.
12. Chan HSL, Thorner PS, Haddad G, Ling V. Immunohisto-chemical detection of p-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990;8:689-704.
13. Dalton WS, Grogan TM, Rybski JA, et al. Immunohisto-chemical detection and quantitation of p-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 1989;73:747-52.
14. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991;9:17-24.
15. Goasguen JE, Dossot J, Fardel O, et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993;81:2394-8.
16. Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992;79:473-6.
17. Michieli M, Raspadori D, Damiani D, et al. The expression of multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia. Br J Haematol 1991;77: 460-5.
18. Benchimol S, Ling V. P-glycoprotein and tumor progression. J Natl Cancer Inst 1994;86:814-6.
19. Weinstein RS, Hansen KK, McBeath RB, Dalton WS. Expression of the MDR1 gene (p-glycoprotein) in breast cancer. Recent Results Cancer Res 1993;127:49-54.
20. Rang Y, Perry RR. Modulatory effects of tamoxifen and recombinant human α-interferon on doxorubicin resistance. Cancer Res 1993;53:3040-5.
21. Verrelle P, Meissonnier F, Fonck Y, et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991; 83:111-6.
22. Hill RP. Tumor progression: potential role of unstable genomic changes. Cancer Metastasis Rev 1990;9:137-47.
23. Weinstein RS, Jakate SM, Dominguez JM, et al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991;51:2720-6.
24. Rofstad EK. Radiation sensitivity in vitro of primary tumors and metastatic lesions of malignant melanoma. Cancer Res 1992-52:4453-7.
25. Ullrich SJ, Anderson CW, Mercer WE, Appelle E. The p53 tumor suppressor protein, a modulator of cell proliferation. J Biol Chem 1992;267:15259-62.
26. Chin K-V, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992;255:459-61.
27. Zastawny RL, Salvino R, Chen J, Benchimol S, Ling V. The core promoter region of the p-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 1993;8:1529-35.
28. Schneider J, Rubio M-P, Barbazan M-J, Rodriguez-Escudero FJ, Seizinger BR, Castresana JS. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 1994;86:850-5.
29. Bradley G, Naik M, Ling V. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res 1989;49:2790-6.
30. Merkel DE, Fuqua SA, Tandon AK, Hill SM, Buzdar AU, McGuire WL. Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. J Clin Oncol 1989;7:1129-36.
31. Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 1989;60:815-8.
32. Krishan A, Sauerteig A, Stein SH. Comparison of three commercially available antibodies for flow cytometric monitoring of P-glycoprotein expression in tumor cells. Cytometry 1991;12:731-42.
33. Charpin C, Vielh P, Duffaud F, et al. Quantitative immunocytochemical assays of p-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst 1994;86:1539-45.
34. Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, Blick M. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 1990;21:787-91.
35. He LR, Huang XF, Hao CY, Lin BY, Wang Y, Gao F. Evaluation of p-glycoprotein expression as a prognostic factor in breast cancer [Abstract 78). Breast Cancer Res Treat 1994;32(suppl):48.